Marie-christine Payen - Infectious Diseases

Author Information

Marie-Christine Payen is affiliated with the Division of Infectious Diseases at CHU Saint-Pierre, Université Libre de Bruxelles (ULB) in Brussels, Belgium. Her work primarily focuses on infectious diseases, with a significant emphasis on tuberculosis and its complications, as well as the performance and efficacy of diagnostic assays for various infectious agents.

Research Contributions

Marie-Christine Payen has made substantial contributions to the field of infectious diseases, particularly in the areas of tuberculosis and SARS-CoV-2. Her research includes evaluating the performance of diagnostic assays, assessing new treatment options for multi-drug resistant tuberculosis, and exploring therapeutic interventions for severe pulmonary tuberculosis. Additionally, her work extends to understanding the complications associated with COVID-19, as evidenced by studies on COVID-19-associated hyperinflammatory syndrome. Her research has been pivotal in improving diagnostic accuracy and treatment efficacy for infectious diseases.

Aliases

Marie-Christine Payen has published under several aliases, including M. Payen, M.-c. Payen, Marie-christine Payen, M. C. Payen, and M C Payen.

Publication and Citation Metrics

Metric	Value
Citation Count	1072
h-index	16
Paper Count	60

Publications:

Evaluation and Modelling of the Performance of an Automated SARS-CoV-2 Antigen Assay According to Sample Type, Target Population and Epidemic Trends

DOI: 10.3390/diagnostics12020447

Year: 2022

Evaluation and modelling of the performance of an automated SARS-CoV-2 antigen assay according to sample type, target population and epidemic trends

DOI: 10.1101/2022.01.14.22269064

Year: 2022

Development, validation and clinical use of a LC-MS/MS method for the simultaneous determination of the nine main antituberculosis drugs in human plasma.

DOI: 10.1016/j.jpba.2022.114776

Year: 2022

Severe pulmonary TB rescued with extracorporeal membrane oxygenation therapy.

DOI: 10.5588/ijtld.21.0505

Year: 2022

Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium

DOI: 10.1371/journal.pone.0249734

Year: 2021

Aortic thrombosis in a patient with COVID-19-associated hyperinflammatory syndrome

DOI: 10.1016/j.ijid.2021.03.081

Year: 2021

TB in the intensive care unit in a low-endemic country.

DOI: 10.5588/ijtld.20.0405

Year: 2021

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.

DOI: 10.1016/j.pulmoe.2021.02.006

Year: 2021

Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

DOI: 10.1186/s12879-021-06745-w

Year: 2021

Tuberculosis and pseudoaneurysms.

DOI: 10.1016/j.medmal.2020.01.013

Year: 2020

How can public health initiatives promote condom use?

How Can ARDS be Prevented in the Context of Infectious Diseases?

How Can Resistance be Managed?

How is Gonorrhea Diagnosed?

How is Dengue Hemorrhagic Fever Diagnosed?

What is Herpes?

Can Lifestyle Changes Help Alleviate Fatigue?

What are Antibiotics?

How Can We Improve Global Health Infrastructure to Combat Infectious Diseases?

How is Treatment Monitored?

Partnered Content Networks

Relevant Topics